Anti-C1q Antibody, IgG
2007601
Ordering Recommendation
Assess risk for lupus nephritis and global SLE disease activity.
Submit With Order
Mnemonic
ANTI-C1Q
Methodology
Semi-Quantitative Enzyme-Linked Immunosorbent Assay
Performed
Mon
Reported
1-8 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
 
Collect
Serum separator tube.  
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Urine or plasma. Contaminated, heat-inactivated, severely hemolyzed or severely lipemic specimens.  
Remarks
 
Stability
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)  
Reference Interval
0-​19 Units Negative
20-​39 Units Equivocal
40 Units or greater Positive
Interpretive Data
The presence of the anti-C1q IgG antibody may be associated with increased risk of lupus nephritis or with systemic lupus erythematosus (SLE) global activity. Anti-C1q antibodies are not specific for SLE; strong clinical correlation with disease is recommended.

See Compliance Statement A: www.aruplab.com/CS
Note
CPT Code(s)
83516
Components
Component Test Code*Component Chart Name
2007602Anti-C1q Antibody, IgG
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Cross References
  • C1q IgG Ab